Nanoviricides, Inc. shares rise 1.31% premarket after announcing NV-387 antiviral drug's potential for treating multiple viral infections.

Nanoviricides, Inc. rose 1.31% in premarket trading, with the company announcing that its antiviral drug NV-387 could potentially help treat a variety of respiratory viral infections, including RSV, COVID, Long COVID, Influenza, and MPOX/Smallpox. The company is focused on advancing NV-387 into Phase II human clinical trials, which has likely contributed to the positive market sentiment.